Literature DB >> 7206363

Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolizing activity for ester-type drugs.

M Inoue, M Morikawa, M Tsuboi, Y Ito, M Sugiura.   

Abstract

In attempts to determine the exact role of intestinal esterase in the body, we purified esterases from human intestinal mucosa and liver, and compared the enzymatic properties and substrate specificities with those of purified esterases. Esterase from human liver was purified 58-fold, by treatment with butanol, DE-52 and DEAE Sephadex A-50 column chromatographies, Sephadex G-200 gel filtration, and isoelectric focusing. The purified preparation showed a single band by polyacylamide gel electrophoresis. The molecular weights of intestinal and hepatic esterases were determined to be 53,000-55,000 and 180,000, respectively, by gel filtration on Sephadex G-200. The activity of the purified intestinal and hepatic esterases was strongly inhibited by diethyl-p-nitrophenyl phosphate and diisopropyl fluorophosphate, and was not inhibited by eserine sulfate and p-chloromercuribenzoate. Moreover, the purified esterases hydrolyzed ester-type drugs such as aspirin, clofibrate, indanyl carbenicillin and procaine. Hepatic esterase had properties similar to those of intestinal esterase with respect to the sensitivity to organophosphate and the substrate specificity. However, the two purified esterases differed in properties such as molecular weight, isoelectric point, thermostability and optimal pH.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7206363     DOI: 10.1254/jjp.30.529

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  11 in total

1.  Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study.

Authors:  J Van Gelder; P Annaert; L Naesens; E De Clercq; G Van den Mooter; R Kinget; P Augustijns
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Absorption and metabolism of procaine by the rat small intestine.

Authors:  J Rummel; H P Büch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

3.  Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.

Authors:  Jiapeng Li; Jian Shi; Jingcheng Xiao; Lana Tran; Xinwen Wang; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2021-12-21       Impact factor: 3.922

Review 4.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 5.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

6.  Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches.

Authors:  Marlene T Kim; Alexander Sedykh; Suman K Chakravarti; Roustem D Saiakhov; Hao Zhu
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

Review 7.  Pharmacokinetics and molecular detoxication.

Authors:  J R Cashman; B Y Perotti; C E Berkman; J Lin
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

8.  Effects of Panax Notoginseng Saponins on Esterases Responsible for Aspirin Hydrolysis In Vitro.

Authors:  Zongxi Sun; Yali Wu; Song Liu; Shaonan Hu; Bo Zhao; Pengyue Li; Shouying Du
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

9.  Inhibitory Influence of Panax notoginseng Saponins on Aspirin Hydrolysis in Human Intestinal Caco-2 Cells.

Authors:  Zongxi Sun; Yali Wu; Bing Yang; Baochen Zhu; Shaonan Hu; Yang Lu; Bo Zhao; Shouying Du
Journal:  Molecules       Date:  2018-02-18       Impact factor: 4.411

10.  Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention.

Authors:  Ranjini Sankaranarayanan; Chaitanya K Valiveti; Rakesh Dachineni; D Ramesh Kumar; Tana Lick; G Jayarama Bhat
Journal:  Mol Med Rep       Date:  2019-11-18       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.